The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | TUXEDO-3: patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors
Matthias Preusser, MD, Medical University of Vienna, Vienna, Austria, discusses findings from the Phase II TUXEDO-3 trial (NCT05865990), which evaluated patritumab deruxtecan (HER3-DXd) in patients with leptomeningeal metastatic disease (LMD) of solid tumors. TUXEDO-3 showed clinically relevant HER3-DXd activity in patients with LMD, with all three cohorts meeting primary endpoints and showing significant response rates and improved survival.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
